欢迎关注凯莱英药闻近日，恒瑞医药申报的HRS-6768注射液获得国家药品监督管理局签发的《药物临床试验批准通知书》，将于近期开展临床试验。HRS-6768是一款靶向成纤维细胞激活蛋白α（FAP-α）的放射性核素偶联药物（RDC），拟开发用于成纤维细胞 ...

战场上收破烂真的能实现财富自由吗 ...

By Madison Rogers/UW News Lab Monday, District 3 representative Joy Hollingsworth got an earful of what it will be like leading the city’s 20-year planning effort of the neighborhood by ...

Meta criticised over ‘chilling’ content moderation changes - The social media giant has announced it is ending third-party ...

Pakistani rupee on Tuesday depreciated by 04 paisa against the US dollar in the interbank trading and closed at Rs278.66 ...

This holiday season, Family Service of Chester County (FSCC) delivered cheer and support to local families in need through ...

KARACHI: The Karachi Port Trust handled 210,220 tons of cargo comprising 128,516 Tons of import cargo and 81,704 ...

“Surrealism is meant for me because I am a pretty realistic person but don’t like all I see,” Gertrude Abercrombie (1909-1977 ...

Shipping activity was report at the port where six ships, Apollon-D, MSC  Positano, MSC Aquarius, Alaa, Amir Gas and Spar ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

在心血管疾病中，心肌纤维化是一个严重的病理问题，影响着成千上万患者的生活质量和生命预期。心肌纤维化是心肌缺血再灌注损伤后的一种常见结果，虽然现有治疗手段在不断进步，但仍然无法有效地逆转这一损伤。最近，来自良渚实验室的研究成果为此病的治疗带来了新的希望。在这项研究中，科学家们首次应用了靶向嵌合抗原受体巨噬细胞（FAP CAR-Ms）疗法，有望改善心肌纤维化的治疗方案。

科技日报报道，良渚实验室的研究团队近日取得了突破性成果。他们与中国科学院动物研究所的专业团队合作，首次提出靶向嵌合抗原受体巨噬细胞疗法（FAP CAR-Ms），用于解决心肌缺血再灌注引起的组织损伤和纤维化问题。相关研究成果已在国际知名期刊《循环研究》上发表。 心肌缺血再灌注损伤是心脏病患者在治疗后面临的一种严重并发症，对患者生存率影响显著。目前，缺乏有效的治疗手段，心脏纤维化成了常见的病理变化，会 ...